Abstract
Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.
| Original language | English |
|---|---|
| Pages (from-to) | 1330-1334 |
| Number of pages | 5 |
| Journal | Experimental Biology and Medicine |
| Volume | 247 |
| Issue number | 15 |
| DOIs | |
| State | Published - Aug 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19
- SARS-CoV-2
- diabetics
- hyperglycemia
- insulin resistance
Fingerprint
Dive into the research topics of 'COVID-19 and diabetes: What do we know so far?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver